BioSpace News Archive

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that four abstracts highlighting ultra-low-field imaging data will be presented at the 2024 International Stroke Conference (ISC), held from February 7–9 in Phoenix.

Revance Therapeutics, Inc. (RVNC), today announced that the company will be participating in the Guggenheim Healthcare Talks, 6th Annual Biotechnology Conference, taking place February 7-8, 2024, in New York, New York.

Tonix Pharmaceuticals (NASDAQ:TNXP) appears to have a potential new weapon against fibromyalgia for the 6-12 million adults in America suffering from its debilitating effects.

Intelivation Technologies, an innovative medical device company with a cutting-edge orthopedic portfolio announced the commercial launch of the Hammerdesis™ Interphalangeal Fusion System in conjunction with their exhibit at the Annual Scientific Meeting of the American College of Foot and Ankle Surgeons, held February 1-4, 2024 in Tampa, Florida.

Cortex announced today the initiation of its RESOLVE-AF trial (NCT05883631), a study formally launched in late October 2023.

Basking Biosciences today announced the close of a $55 million financing.

Dyadic International, Inc. today announced that its management will be attending the following events during the month of February 2024.

SS Innovations International, Inc. (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, conducted a groundbreaking live telesurgery demonstration at the inaugural SS Innovations Multi-Specialty Robotic Surgical Conference (SMRSC) that was held in Gurugram, Haryana, India on January 19 and 20, 2024.

Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will present at the Virtual Investor New to the Street Event on Wednesday, February 7, 2024 at 10:00 AM ET.

Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (“GI”) disorders, announced today that the company will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13th, 2024.